Stratos reached its milestone by demonstrating nanopore sequencing with its proprietary expandable nucleotides, called X-NTPs.
NEW YORK (GenomeWeb) – When Roche announced last month that it planned to acquire nanopore sequencing startup Genia for up to $350 million, unbeknownst to the public
NEW YORK (GenomeWeb) — Roche said today that it has made a strategic investment in nanopore sequencing startup Stratos Genomics and is collaborating to further develop the firm's sequencing chemistry.
After developing the chemistry for its sequencing-by-expansion nanopore technology for several years, Stratos Genomics is ready to grow its development and commercialization efforts.
NEW YORK (GenomeWeb News) – Stratos Genomics today announced it has closed on $2 million in financing to support the further development of, and "strategic discussions" related to the Seattle-based firm's DNA sequencing technology.
Stratos converts DNA into a longer polymer called an "Xpandomer," which encodes the base sequence through reporter molecules that have a high signal-to-noise ratio.
The funding follows $4 million raised last year and will be used to further develop the firm's ultra-low-cost nucleic acid sequencing technology.
The firm will use the funds to support further development of its "sequencing by expansion" technology.
Seattle-based Stratos Genomics, a 2007 spin-off from the Stratos Group, is working on a new method called sequencing by expansion.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.